SAN ANTONIO — Fertility preservation and/or assisted reproductive technologies do not increase the risk for short-term cancer recurrence in young women with early hormone receptor (HR)-positive breast ...

Biomarkers are measurable indicators that can be tested to reveal important details about a cancer. Information about these biomarkers can help guide the best treatment for you, predict your response ...

Treatment for hormone receptorpositive (HR-positive)/HER2-negative metastatic breast cancer often starts with hormone therapy (tamoxifen or an aromatase inhibitor ...

Older women with high-risk hormone receptor-positive breast cancer showed no significant survival benefit from adjuvant chemotherapy 4 or 8 years later. The chemotherapy group experienced four times ...

Not all metastatic breast cancers behave similarly in the body. Each subtype of breast cancer has distinct characteristics, which make them more likely to behave in ...

Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year Approval brings Daiichi ...

Afuresertib plus fulvestrant cuts progression risk in HR+/HER2– metastatic breast cancer with PI3K/AKT/PTEN alterations, with ...

In a German cohort of women with hormone receptor-positive early breast cancer, more than two-thirds (68%) were adherent to their endocrine therapy regimen after 5 years, resulting in significantly ...

Avan Armaghani, MD, reviews three key topics in the management of hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer to be explored at this year’s ...

Please provide your email address to receive an email when new articles are posted on . Preoperative breast MRI provides no benefit in stage I or II hormone receptor-negative breast cancer. Five-year ...